Antibody treatment for RSV in infants show promise

28 June 2021
baby_hospital_infant_big

Nirsevimab, a promising biologic for the passive inoculation of preterm infants against respiratory syncytial virus (RSV), has scored positive results in the Phase II/III MEDLEY trial.

Under development by AstraZeneca (LSE: AZN) and Sanofi (Euronext: SAN), the therapy is designed to be administered to preterm infants or those with chronic lung disease or congenital heart disease entering their first RSV season.

In the study, nirsevimab showed a similar safety and tolerability profile to Synagis (palivizumab), an injectable option for infants marketed by Swedish Orphan Biocitrum (STO: SOBI).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology